Evidence-based

References

Every statement on ibdpsc.org is grounded in the published medical literature. Below, the key points are grouped by topic and linked to the peer-reviewed studies that support them. Sources were retrieved from a curated IBD with primary sclerosing cholangitis research library and verified against the U.S. National Library of Medicine (PubMed); none are retracted. Last verified July 2026.

PSC-IBD — the distinct colitis

The colitis of IBD-PSC is a distinct phenotype — often extensive yet mild, right-sided, with rectal sparing and backwash ileitis.1–5

Colorectal cancer — risk & surveillance

IBD-PSC carries a markedly higher colorectal-cancer risk, more often right-sided, which is why annual surveillance colonoscopy begins at PSC diagnosis.6–10

Biliary & gallbladder cancer

PSC also raises the risk of bile-duct (cholangiocarcinoma) and gallbladder cancer, monitored separately by the liver team.11–13

Diagnosis & natural history of PSC

PSC is a chronic, slowly progressive bile-duct disease strongly linked to inflammatory bowel disease.14, 15

Liver disease — management & transplant

PSC is followed by a hepatologist with liver tests and MRCP; for advanced disease, liver transplantation is the most effective treatment.16–21

Colitis therapy in PSC-IBD

Day-to-day colitis in IBD-PSC is managed with the same medical therapies used for IBD, guided by disease activity.22, 23

Surgery — colectomy, IPAA & the pouch

People with IBD-PSC who need surgery can undergo ileal pouch-anal anastomosis; chronic pouchitis is more common in PSC and timing is coordinated with the liver disease.24–30

Children with PSC-IBD

PSC-IBD also occurs in children and is followed with the same attention to colon and liver.31, 32

References

  1. Boonstra K, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2270-6. PMID: 22407885.
  2. Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC Phenotypes of PSC-IBD. Curr Gastroenterol Rep. 2018;20(4):16. PMID: 29594739.
  3. de Vries AB, et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956-71. PMID: 25684965.
  4. Barberio B, et al. Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Gastroenterology. 2021;161(6):1865-1877. PMID: 34425093.
  5. Zhang Y, et al. Prevalence of inflammatory bowel disease in patients with primary sclerosing cholangitis: A systematic review and meta-analysis. Liver Int. 2022;42(8):1814-1822. PMID: 35689520.
  6. Zheng HH, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Eur J Gastroenterol Hepatol. 2016;28(4):383-90. PMID: 26938805.
  7. Das TS, et al. Risk of colorectal cancer in patients with primary sclerosing cholangitis and concomitant inflammatory bowel disease compared with primary sclerosing cholangitis only. Hepatol Res. 2024;54(9):807-816. PMID: 38419394.
  8. Claessen MM, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis. 2009;15(9):1331-6. PMID: 19229982.
  9. Sokol H, Chazouilleres O. Colorectal neoplasia in PSC-IBD patients: are times changing?. Liver Int. 2012;32(2):175-6. PMID: 22226230.
  10. Jamil OK, et al. Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis. Ther Adv Gastroenterol. 2023;16:17562848231184985. PMID: 37692199.
  11. Villard C, et al. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J Hepatol. 2023;78(3):604-613. PMID: 36410555.
  12. Horsley-Silva JL, et al. An update on cancer risk and surveillance in primary sclerosing cholangitis. Liver Int. 2017;37(8):1103-1109. PMID: 28028930.
  13. Buckles DC, et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002;97(5):1138-42. PMID: 12014717.
  14. Fricker ZP, Lichtenstein DR. Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. Dig Dis Sci. 2019;64(3):632-642. PMID: 30725292.
  15. Wiesner RH, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;10(4):430-6. PMID: 2777204.
  16. Eaton JE, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011;106(9):1638-45. PMID: 21556038.
  17. Singh S, et al. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19(8):1631-8. PMID: 23665966.
  18. Graziadei IW, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999;30(5):1121-7. PMID: 10534330.
  19. Leung KK, et al. Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions. Semin Liver Dis. 2021;41(3):409-420. PMID: 34182588.
  20. Chapman RW, Williamson KD. Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?. Curr Hepatol Rep. 2017;16(2):124-129. PMID: 28706774.
  21. Barkin JA, Levy C, Souto EO. Endoscopic Management of Primary Sclerosing Cholangitis. Ann Hepatol. 2017;16(6):842-850. PMID: 29055922.
  22. Shah A, et al. Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis. Hepatol Commun. 2024;8(1). PMID: 38206197.
  23. Tse CS, et al. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(2):190-195. PMID: 29808485.
  24. Mathis KL, et al. Short- and long-term surgical outcomes in patients undergoing proctocolectomy with ileal pouch-anal anastomosis in the setting of primary sclerosing cholangitis. Dis Colon Rectum. 2011;54(7):787-92. PMID: 21654244.
  25. Wasmuth HH, et al. Primary sclerosing cholangitis and extraintestinal manifestations in patients with ulcerative colitis and ileal pouch-anal anastomosis. J Gastrointest Surg. 2010;14(7):1099-104. PMID: 20480253.
  26. Imam MH, et al. Neoplasia in the ileoanal pouch following colectomy in patients with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis. 2014;8(10):1294-9. PMID: 24768559.
  27. Nordenvall C, et al. Restorative Surgery in Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis Following a Colectomy. Inflamm Bowel Dis. 2018;24(3):624-632. PMID: 29462381.
  28. Ong J, et al. Does colectomy affect the progression of primary sclerosing cholangitis? A systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2018;11(4):277-283. PMID: 30425805.
  29. Nordenvall C, Bergquist A. Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. Aliment Pharmacol Ther. 2018;47(3):441-442. PMID: 29314129.
  30. Mol B, et al. Proctocolectomy with permanent ileostomy is associated with improved transplant-free survival in patients with PSC. JHEP Rep. 2026;8(3):101700. PMID: 41757378.
  31. Miloh T, et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009;7(2):239-45. PMID: 19121649.
  32. Deneau MR, et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology. 2017;66(2):518-527. PMID: 28390159.

Compiled by IBDology. Citations are provided for transparency and education and are not a substitute for advice from your own care team.